1. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6
- Author
-
Stefan Schäfer, Crystal E. Berger, Christopher C. Benz, Eric Verdin, Corina Marx, Manfred Jung, Laura Saunders, and Gary K. Scott
- Subjects
Untranslated region ,Niacinamide ,Cancer Research ,Small interfering RNA ,Receptor, ErbB-2 ,RNA Stability ,Molecular Sequence Data ,Biology ,Histone Deacetylase 6 ,Hydroxamic Acids ,Histone Deacetylases ,Article ,Cytosol ,Cell Line, Tumor ,Humans ,RNA, Messenger ,Enzyme Inhibitors ,skin and connective tissue diseases ,Promoter Regions, Genetic ,Molecular Biology ,neoplasms ,3' Untranslated Regions ,AU-rich element ,Messenger RNA ,Gene knockdown ,Base Sequence ,Three prime untranslated region ,RNA ,Molecular biology ,Gene Expression Regulation, Neoplastic ,Protein Transport ,Oncology ,ELAV Proteins ,Cancer research ,Histone deacetylase - Abstract
In addition to repressing ERBB2 promoter function, histone deacetylase (HDAC) inhibitors induce the accelerated decay of mature ERBB2 transcripts; the mechanism mediating this transcript destabilization is unknown but depends on the 3′ untranslated region (UTR) of ERBB2 mRNA. Using ERBB2-overexpressing human breast cancer cells (SKBR3), the mRNA stability factor HuR was shown to support ERBB2 transcript integrity, bind and endogenously associate with a conserved U-rich element within the ERBB2 transcript 3′ UTR, coimmunoprecipitate with RNA-associated HDAC activity, and colocalize with HDAC6. HDAC6 also coimmunoprecipitates with HuR in an RNA-dependent manner and within 6 hours of exposure to a pan-HDAC inhibitor dose, that does not significantly alter cytosolic HuR levels or HuR binding to ERBB2 mRNA. Cellular ERBB2 transcript levels decline while remaining physically associated with HDAC6. Knockdown of HDAC6 protein by small interfering RNA partially suppressed the ERBB2 transcript decay induced by either pan-HDAC or HDAC6-selective enzymatic inhibitors. Three novel hydroxamates, ST71, ST17, and ST80 were synthesized and shown to inhibit HDAC6 with 14-fold to 31-fold greater selectivity over their binding and inhibition of HDAC1. Unlike more potent pan-HDAC inhibitors, these HDAC6-selective inhibitors produced dose-dependent growth arrest of ERBB2-overexpressing breast cancer cells by accelerating the decay of mature ERBB2 mRNA without repressing ERBB2 promoter function. In sum, these findings point to the therapeutic potential of HuR and HDAC6-selective inhibitors, contrasting ERBB2 stability effects induced by HDAC6 enzymatic inhibition and HDAC6 protein knockdown, and show that ERBB2 transcript stability mechanisms include exploitable targets for the development of novel anticancer therapies. (Mol Cancer Res 2008;6(7):1250–8)
- Published
- 2008